Literature DB >> 5317446

Chemotherapeutic studies on Litomosoides carinii infection of Mastomys natalensis. 2. The activity of drugs against microfilariae.

G Lämmler, H Herzog, H R Schütze.   

Abstract

Comparative investigations of the chemotherapeutic activity of various filaricidal compounds and other anthelmintics were made with Litomosoides carinii infections in Mastomys natalensis, special consideration being given to the microfilaricidal activity of the compounds. Diethylcarbamazine, cyclohexanecarboxylic acid-N-methylpiperazide citrate (HOE 28637a), tetrahydropyranecarboxylic acid-N-methylpiperazide citrate (HOE 29691a), (+/-)-tetramisole, (-)-tetramisole (levamisole), and metrifonate proved highly effective against microfilariae whereas gentian violet, methylene violet, and the anthelmintics metyridine, disophenol, pyrantel tartrate, methylpyrantel tartrate and parbendazole showed no, or only inadequate, activity. The usefulness of L. carinii infections in M. natalensis is discussed and is recommended as a model for chemotherapeutic screening tests and for the quantitative evaluation of microfilaricidal activity.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5317446      PMCID: PMC2427873     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  3 in total

1.  Evaluation of microfilaricidal effects in the cornea from topically applied drugs in ocular onchocerciasis: Trials with levamisole and mebendazole.

Authors:  B R Jones; J Anderson; H Fuglsang
Journal:  Br J Ophthalmol       Date:  1978-07       Impact factor: 4.638

2.  Treatment of filariasis-diethylcarbamazine and its congeners.

Authors:  S Sharma
Journal:  Pharm Res       Date:  1986-04       Impact factor: 4.200

3.  Expression of five acetylcholine receptor subunit genes in Brugia malayi adult worms.

Authors:  Ben-Wen Li; Amy C Rush; Gary J Weil
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-06-23       Impact factor: 4.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.